Medindia

X

Reportlinker Adds Regenerative Medicines: Bone and Joint Applications

Wednesday, November 4, 2009 General News J E 4
Advertisement


NEW YORK, Nov. 3 Reportlinker.com announces that a new market research report is available in its catalogue.

Regenerative Medicines: Bone and Joint Applications

http://www.reportlinker.com/p0157460/Regenerative-Medicines-Bone-and-Joint-Applications.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

Provides a comprehensive overview of the global market for regenerative medicines for bone and joint applications

Offers the background for demographics underlying the market for bone and joint products

Contains global market forecasts for regenerative medicines for bone and joint applications, with trends and forecasts for growth through 2014

Describes the leading bone and joint diseases and disorders using regenerative technologies, including incidence and current methods of treatment

Discusses regulatory issues affecting regenerative medicine products

Profiles leading and emerging companies.

Chapter- 1: INTRODUCTION -- Complimentary

OBJECTIVES AND GOALS OF STUDY 1

INTENDED AUDIENCE 2

SCOPE OF REPORT 2

METHODOLOGY 3

INFORMATION SOURCES 3

ANALYST CREDENTIALS 3

RELATED BCC REPORTS 3

BCC ONLINE SERVICES 4

DISCLAIMER 4

Chapter-2: SUMMARY

SUMMARY (CONTINUED) 5

SUMMARY TABLE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, THROUGH 2014 ($ MILLIONS) 6

SUMMARY FIGURE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, 2007-2014 ($ MILLIONS) 6

Chapter-3: OVERVIEW AND OVERALL STATUS OF THE INDUSTRY

TOTAL SCOPE OF REGENERATIVE MEDICINE MARKET 7

TABLE 1 FUNCTIONAL ACTIVITIES WITH REGENERATIVE MEDICINE SECTOR 8

HOW REGENERATIVE MEDICINE WORKS 8

TISSUES AND ORGANS ON DEMAND 9

ORGAN REPLACEMENT IS A $100 BILLION PER YEAR BUSINESS 10

EXAMPLES OF IMPACT ON EXISTING CONDITIONS AND DISEASES 10

BARRIERS TO REGENERATIVE MEDICINE 11

CURRENT R&D PRIORITIES 12

TABLE 2 PRINCIPAL REGENERATIVE MEDICINE BUSINESS R&D FOCUSES 13

TABLE 3 20-YEAR PLANNING HORIZON FOR REGENERATIVE MEDICINE BUSINESS: LIKELY DEVELOPMENTS, 2015-2030 14

TOTAL OUTPUT OF THE SECTOR 15

REGENERATIVE MEDICINE AND HEALTHCARE ECONOMICS 15

POPULATION TRENDS 16

MARKET TIMING 16

OVERSEAS INITIATIVES 17

Chapter-4: PRINCIPLE APPROACHES TO REGENERATIVE MEDICINE

PRINCIPLE APPROACHES TO REGENERATIVE MEDICINE 18

HUMAN SUBSTANCES 19

CELLS AND TISSUES 19

TISSUE ENGINEERING 19

Importance of Scaffolding in Tissue Engineering 20

Blood Vessel Scaffolding 21

Center for Integration of Medicine and Innovative Technology (CIMIT) 21

TABLE 4 PRINCIPLE RESEARCH PROJECTS OF CIMIT IN THE TISSUE-ENGINEERING AND BIOMATERIALS FIELDS, 2008-2010 22

Massachusetts General Hospital 22

Duke University Stem Cell and Regenerative Medicine Program 23

EMBRYONIC STEM CELLS 23

THERAPEUTIC CLONING 24

ADULT STEM CELLS: JUST AS GOOD AS EMBRYONIC STEM CELLS 24

GENZYME 24

UNIVERSITY OF MINNESOTA STEM CELL INSTITUTE 25

STEM CELL RESEARCH PATENTS AND EFFECT ON STEM CELL MARKETERS 26

SETTING THE STAGE FOR REGENERATIVE MEDICINE TO TREAT BONE AND JOINT DISORDERS 26

NOVEL MATERIALS 27

GENE THERAPY 27

Gene Therapy Trials Targeting Bone and Joint Diseases and Disorders 28

BIOREACTOR USE IN REGENERATIVE MEDICINE 29

TABLE 5 COMMERCIAL SUPPLIERS OF BIOREACTORS FOR USE IN REGENERATIVE MEDICINE 29

THE IMPACT OF GENOMICS 30

Chapter-5: PRODUCTS AND TECHNOLOGIES: CATEGORIES OF REGENERATIVE MEDICINE

GENE- AND PROTEIN-BASED APPROACHES 31

ANTIBODIES 31

The Importance of Antibody Drugs 32

Advantages of Monoclonal Antibody Drugs 33

Antibodies and Osteoarthritis 34

GROWTH FACTORS 35

GROWTH FACTORS (CONTINUED) 36

HOW BMPS FUNCTION 37

TABLE 6 BONE MORPHOGENETIC PROTEINS 38

Clinical Uses 38

Companies 39

CELLS AND TISSUES 40

TISSUE ENGINEERING 40

ARTIFICIAL SKIN 41

CARTILAGE 42

OTHER APPROACHES TO CARTILAGE 43

BIOSYNTHETIC COMPOSITES FOR CARTILAGE REPAIR 44

THE MARKET FOR TISSUE-ENGINEERED CARTILAGE PRODUCTS 44

TABLE 7 U.S. MARKET FOR TISSUE-ENGINEERED CARTILAGE PRODUCTS, THROUGH 2014 ($ MILLIONS) 45

OTHER PRODUCTS 45

CREATION OF ENTIRE ORGANS 45

CREATION OF ENTIRE ORGANS (CONTINUED) 46

EMBRYONIC STEM CELLS 47

NOVEL MATERIALS AND BIOMATERIALS 48

Chapter-6: STEM CELL THERAPIES AND REGENERATIVE MEDICINE

STEM CELLS AS POTENTIAL REPLACEMENT CELLS 49

TECHNICAL IMPEDIMENTS 50

OVERVIEW OF FUNDING 51

TABLE 8 FEDERAL FUNDING FOR STEM CELL RESEARCH, THROUGH 2008 ($ MILLIONS) 52

STATE-LEVEL INITIATIVES FOR STEM CELL RESEARCH 52

TABLE 9 STATE LEVEL PROGRAMS FOCUSED ON STEM CELL RESEARCH 53

POTENTIAL APPLICATIONS: CURRENT STATUS 53

IN VIVO REPROGRAMMING 54

UMBILICAL CORD BLOOD STEM CELLS 55

Recent Research Developments 55

INDUCED PLURIPOTENT STEM CELLS 56

Recent Research Developments 56

Adult Multipotent Stem Cells 57

Embryonic Stem Cells 57

Embryonic Stem Cells (Continued) 58

GERON AND THE FIRST HUMAN TRIALS 59

GERON AND THE FIRST HUMAN TRIALS (CONTINUED) 60

OTHER STEM CELL RESEARCH 61

STATUS OF OTHER CLINICAL TRIALS 62

STEM CELL THERAPY FOR ALS 63

STEM CELL THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY 64

STEM CELL THERAPY AND BONE MARROW TRANSPLANTS 65

Stem Cell Therapy and ... (Continued) 66

Chapter-7: REGENERATIVE PRODUCTS TO TREAT BONE DISEASES

REGENERATIVE PRODUCTS TO TREAT BONE DISEASES 67

OSTEOBIOLOGICS 67

BONE GRAFTS 68

TABLE 10 CHARACTERISTICS OF IDEAL BONE GRAFT MATERIAL 69

TABLE 11 U.S. BONE GRAFT PROCEDURE VOLUMES BY APPLICATION, THROUGH 2014 70

TABLE 12 U.S. BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, THROUGH 2014 70

TABLE 13 BONE GRAFT MATERIALS 71

TABLE 13 (CONTINUED) 72

TABLE 14 SUBSTITUTE BONE GRAFTS 72

AUTOGRAFTS 73

BIOSEED GRAFTS 73

ALLOGRAFTS 74

Allografts (Continued) 75

DEMINERALIZED BONE MATRIX PRODUCTS 76

TABLE 15 SELECTED DBM PRODUCTS AND PERCENTAGE OF DEMINERALIZED BONE MATRIX 77

Accell 77

AlphaGRAFT 77

Allomatrix 78

Grafton DBM 78

DBX 78

DynaBlast and DynaGraft-D 78

Graftech 78

Grafton 78

Opteform 79

OrthoBlast II 79

Osteofil 79

Solo Cervical Allograft 80

XENOGRAFTS 80

THE MARKET FOR ALLOGRAFTS 80

TABLE 16 U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2014 ($ MILLIONS) 80

FIGURE 1 U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, 2007-2014 ($ MILLIONS) 81

CELL-BASED BONE GRAFT SUBSTITUTES 82

FACTOR-BASED BONE GRAFT SUBSTITUTES 82

Factor-based Bone Graft Substitutes (Continued) 83

BONE MORPHOGENIC PROTEINS 84

INDUCTOS 84

INFUSE BONE GRAFT 85

OP-1 IMPLANT 85

CERAMIC-BASED BONE GRAFT SUBSTITUTES 86

TYPES OF CERAMICS 86

Alpha-BSM 87

BioGran 87

Bio-Oss 88

BoneSource 88

Calcigen S 88

Collagraft Strip Bone Graft Matrix 88

Conduit TCP Granules 89

IsoTis Products 89

Mimix Bone Substitute Material 90

Norian SRS 90

OsteoGraf 90

Osteoset 90

OsteoStim Resorbable Bone Graft Substitute 91

PerioGlas 91

Pro Osteon Implant 91

Vitoss 91

POLYMER-BASED BONE GRAFT SUBSTITUTES 92

CORTOSS 92

HEALOS 93

IMMIX EXTENDERS AND IMMIX CB 94

THE MARKET FOR BONE GRAFT PRODUCTS 94

TABLE 17 WORLDWIDE MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2014 ($ MILLIONS) 94

FIGURE 2 WORLDWIDE MARKET FOR BONE REPLACEMENT PRODUCTS, 2007-2014 ($ MILLIONS) 95

TABLE 18 U.S. MARKET FOR BONE-REPLACEMENT PRODUCTS, THROUGH 2014 ($ MILLIONS) 96

FIGURE 3 U.S. MARKET FOR BONE-REPLACEMENT PRODUCTS, 2007-2014 ($ MILLIONS) 96

REGENERATIVE MEDICINE PRODUCTS IN DEVELOPMENT FOR BONE APPLICATIONS 96

BIOLOGIC/SYNTHETIC GRAFTS 97

CHRYSALIN 97

Chrysalin (Continued) 98

Chrysalin (Continued) 99

Chapter-8: REGENERATIVE APPLICATIONS FOR BONES AND JOINTS

MATERIALS FOR BONE TISSUE REPAIR 100

INHERENT REGENERATION OF BONE 100

OVERALL SIZE OF BONE GRAFT BUSINESS 101

BONE GRAFT SUBSTITUTES 102

ALLOGRAFT TISSUE 103

OTHER OSTEOCONDUCTIVE BONE GRAFT SUBSTITUTES 104

HYDROGELS AND REGENERATION 105

COMPOSITION AND METHOD FOR SELF-ASSEMBLY AND MINERALIZATION OF PEPTIDE AMPHIPHILES 106

CHONDROITINASE ABC I POLYNUCLEOTIDES 107

Abstract 107

TRANSDISCAL ADMINISTRATION OF CYCLINE COMPOUNDS 107

Abstract 107

COMPOSITION AND METHOD FOR PREPARING BIOCOMPATIBLE SURFACES 108

Abstract 108

SPINAL MOBILITY PRESERVATION APPARATUS HAVING AN EXPANDABLE MEMBRANE 108

Abstract 108

MAJOR DISEASES AND CONDITIONS AFFECTING BONES 109

OSTEOPOROSIS 110

Currently Available Products to Treat Osteoporosis 111

Bisphosphonates 111

Fosamax 112

Boniva 113

TABLE 19 DRUGS USED TO TREAT OSTEOPOROSIS 113

Hormones 114

Evista 114

Forteo 114

Forteo (Continued) 115

Forteo (Continued) 116

Miacalcin 117

STEROIDS AND OSTEOPOROSIS 117

Glucocorticoids 118

THE MARKET FOR PRODUCTS TO TREAT OSTEOPOROSIS. 118

TABLE 20 WORLDWIDE MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, THROUGH 2014 ($ MILLIONS) 119

FIGURE 4 WORLDWIDE MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, 2007-2014 ($ MILLIONS) 119

PAGET'S DISEASE 119

DRUGS CURRENTLY AVAILABLE TO TREAT PAGET'S DISEASE 120

Actonel 120

Aredia 120

Skelid 121

Zometa 121

THE MARKET FOR PRODUCTS TO TREAT PAGET'S DISEASE 121

TABLE 21 WORLDWIDE MARKET FOR DRUGS TO TREAT PAGET'S DISEASE, THROUGH 2014 ($ MILLIONS) 121

FIGURE 5 WORLDWIDE MARKET FOR DRUGS TO TREAT PAGET'S DISEASE, 2007-2014 ($ MILLIONS) 122

INJURIES AND DEGENERATIVE CONDITIONS 122

HIP FRACTURES 123

TABLE 22 WORLDWIDE HIP FRACTURE VOLUMES, THROUGH 2014 124

TABLE 23 U.S. HIP FRACTURE VOLUMES, THROUGH 2014 124

TRADITIONAL TREATMENTS FOR BONE AND JOINT DISORDERS 124

TABLE 24 U.S. MARKET SHARES FOR MUSCULOSKELETAL PRODUCTS, 2008 (%) 125

TABLE 25 U.S. RECONSTRUCTIVE DEVICE MARKET, 2008 (%) 125

MARKET LEADERS 125

JOINT-REPLACEMENT SURGERY 126

TABLE 26 HIP REPLACEMENT PROCEDURE VOLUMES, U.S., THROUGH 2014 126

TABLE 27 HISTORICAL RATES OF HIP REPLACEMENT IN SIX MAJOR STATES, 2001 126

TABLE 28 WORLDWIDE HIP REPLACEMENT MARKET, THROUGH 2014 ($ MILLIONS) 127

FIGURE 6 WORLDWIDE HIP REPLACEMENT MARKET, 2007-2014 ($ MILLIONS) 127

TABLE 29 U.S. HIP REPLACEMENT MARKET, THROUGH 2014 ($ MILLIONS) 127

FIGURE 7 U.S. HIP REPLACEMENT MARKET, 2007-2014 ($ MILLIONS) 128

KNEE REPLACEMENTS 128

TABLE 30 WORLDWIDE KNEE-REPLACEMENT PROCEDURE VOLUMES, THROUGH 2014 129

TABLE 31 U.S. KNEE REPLACEMENT PROCEDURE VOLUMES, THROUGH 2014 129

TABLE 32 WORLDWIDE KNEE REPLACEMENT MARKET, THROUGH 2014 ($ MILLIONS) 129

FIGURE 8 WORLDWIDE KNEE REPLACEMENT MARKET, 2007-2014 ($ MILLIONS) 130

TABLE 33 U.S. KNEE REPLACEMENT MARKET, THROUGH 2014 ($ MILLIONS) 130

FIGURE 9 U.S. KNEE REPLACEMENT MARKET, 2007-2014 ($ MILLIONS) 131

TABLE 34 U.S. MARKET FOR UNICONDYLAR KNEE REPLACEMENT, THROUGH 2014 ($ MILLIONS) 131

FIGURE 10 U.S. MARKET FOR UNICONDYLAR KNEE REPLACEMENT, 2007-2014 ($ MILLIONS) 132

NATURAL THERAPEUTIC TREATMENTS FOR ARTHRITIS 132

IMAGING AND REGENERATION 133

IMAGING AND REGENERATION (CONTINUED) 134

Chapter-9: ELECTRICAL BONE GROWTH STIMULATOR MARKET

OVERVIEW 135

SCIENTIFIC BASIS 136

ULTRASONIC OSTEOGENESIS STIMULATORS FOR BONE HEALING 137

MARKETERS OF INVASIVE AND NONINVASIVE ELECTRICAL BONE GROWTH STIMULATORS 138

BIOMET 138

ORTHOFIX 139

DJO, INC. 140

SMITH & NEPHEW 141

MARKET SIZE 141

TABLE 35 WORLDWIDE MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2014 ($ MILLIONS) 141

TABLE 36 U.S. MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2007 ($ MILLIONS) 142

Chapter-10: ORTHOPEDICS FDA CLEARANCES AND NEW PRODUCT DEVELOPMENT

SUPPLIERS OF REGENERATIVE BONE AND JOINT PRODUCTS 143

TABLE 37 RECENTLY APPROVED ORTHOPEDIC BONE AND JOINT DEVICES BY PRODUCT, COMPANY, AND APPROVAL DATE, 2008-2009 144

TABLE 37 (CONTINUED) 145

TABLE 37 (CONTINUED) 146

TABLE 37 (CONTINUED) 147

TABLE 37 (CONTINUED) 148

TABLE 37 (CONTINUED) 149

TABLE 37 (CONTINUED) 150

TABLE 37 (CONTINUED) 151

TABLE 37 (CONTINUED) 152

TABLE 37 (CONTINUED) 153

TABLE 37 (CONTINUED) 154

TABLE 37 (CONTINUED) 155

TABLE 37 (CONTINUED) 156

TABLE 37 (CONTINUED) 157

TABLE 37 (CONTINUED) 158

Chapter-11: MARKET FOR TISSUE ENGINEERING PRODUCTS

TISSUE ENGINEERING AND CELL THERAPY 159

RESEARCH INITIATIVES 160

RESEARCH INITIATIVES (CONTINUED) 161

RESEARCH INITIATIVES (CONTINUED) 162

Chapter-12: REGENERATIVE CONCEPTS AND PRODUCTS IN DENTISTRY

OVERVIEW 163

INDICATIONS AND HISTORY 163

CHARACTERISTICS AND MATERIALS 164

BARRIER MEMBRANES 164

NON-RESORBABLE 164

RESORBABLE 164

COLLAGEN RESORBABLE MEMBRANES 165

SYNTHETIC RESORBABLE MEMBRANES 165

Chapter-13: SKIN TECHNOLOGIES

SKIN TECHNOLOGIES (CONTINUED) 166

SKIN-LIKE TISSUE DEVELOPED FROM HUMAN EMBRYONIC STEM CELLS 167

TABLE 38 SALES OF ENGINEERED SKIN GRAFTS AND REPLACEMENTS, THROUGH 2014 ($ MILLIONS) 168

Chapter-14: NEUROLOGICAL APPLICATIONS IN REGENERATIVE MEDICINE

OVERVIEW 169

NEURODEGENERATIVE DISEASES 169

CURRENT CONVENTIONAL THERAPIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE SYMPTOMS 169

SPINAL CORD INJURY, NEURODEGENERATIVE DISEASES, AND REGENERATIVE POTENTIAL 170

SPINAL CORD INJURY, ... (CONTINUED) 171

UNIVERSITY OF SOUTHERN CALIFORNIA (USC) 172

Chapter-15: REGENERATIVE MEDICINE AND APPLICATIONS IN CARDIAC CARE

OVERVIEW 173

STEM CELLS FOR THE FUTURE TREATMENT OF HEART DISEASE 173

PARTICULAR R&D PRIORITIES 174

PARTICULAR R&D PRIORITIES (CONTINUED) 175

STEM CELLS AND BIOLOGICAL PACEMAKERS 176

HEART PROGENITOR CELLS DEVELOPED FROM EMBRYONIC STEM CELLS 176

OTHER CURRENT REGENERATIVE MEDICINE AS IT RELATES TO THE HEART 177

OTHER CURRENT REGENERATIVE ...(CONTINUED) 178

Chapter-16: REGENERATIVE MEDICINE AND DIABETES

BACKGROUND 179

POSSIBLE APPLICATIONS FOR REGENERATIVE MEDICINE 179

POSSIBLE APPLICATIONS FOR ... (CONTINUED) 180

Chapter-17: FDA APPROVED CLINICAL TRIALS INVOLVING REGENERATIVE MEDICINE

CURRENT STATUS OF THE REGENERATIVE MEDICINE BUSINESS 181

REGULATORY ENVIRONMENT 181

REGULATORY ENVIRONMENT (CONTINUED) 182

STATUS OF RESEARCH AND CLINICAL TRIALS 183

ANALYSIS OF CLINICAL TRIALS 184

TABLE 39 REGENERATIVE MEDICINE CLINICAL TRIALS BY MAJOR CATEGORY 185

TABLE 40 CURRENT CLINICAL TRIALS IN THE FIELD OF REGENERATIVE MEDICINE STATUS, CONDITIONS, INTERVENTION, AND SPONSOR 185

TABLE 40 (CONTINUED) 186

TABLE 40 (CONTINUED) 187

TABLE 40 (CONTINUED) 188

TABLE 40 (CONTINUED) 189

TABLE 40 (CONTINUED) 190

TABLE 40 (CONTINUED) 191

TABLE 40 (CONTINUED) 192

TABLE 40 (CONTINUED) 193

TABLE 40 (CONTINUED) 194

TABLE 40 (CONTINUED) 195

TABLE 40 (CONTINUED) 196

TABLE 40 (CONTINUED) 197

TABLE 40 (CONTINUED) 198

TABLE 40 (CONTINUED) 199

TABLE 40 (CONTINUED) 200

TABLE 40 (CONTINUED) 201

TABLE 40 (CONTINUED) 202

TABLE 40 (CONTINUED) 203

TABLE 40 (CONTINUED) 204

TABLE 40 (CONTINUED) 205

TABLE 40 (CONTINUED) 206

TABLE 40 (CONTINUED) 207

TABLE 40 (CONTINUED) 208

TABLE 40 (CONTINUED) 209

Chapter-18: OVERSEAS ACTIVITIES

DOMESTIC VERSUS OVERSEAS REGENERATIVE MEDICINE COMPANIES 210

JAPAN 210

EUROPE 211

AUSTRALIA AND CHINA 212

Chapter-19: PATENT ANALYSIS

ANALYSIS 213

TISSUE ENGINEERING PATENTS 213

TABLE 41 MOST FREQUENTLY CITED PATENT ASSIGNEES IN TISSUE ENGINEERING FIELD 214

GEOGRAPHIC DISTRIBUTION 214

TABLE 42 WORLD DISTRIBUTION OF REGENERATIVE MEDICINE PATENTS ISSUED, 1985-2009 (%) 215

RECENT PATENTS 215

DIRECT DIFFERENTIATION METHOD FOR MAKING CARDIOMYOCYTES FROM HUMAN EMBRYONIC STEM CELLS 215

Abstract 215

METHOD FOR PREPARING NOVEL TRANSCRIPTION FACTORS AND USE 216

Abstract 216

ENDODERM CELLS FROM HUMAN EMBRYONIC STEM CELLS 216

Abstract 216

GENES WITH ES CELL-SPECIFIC EXPRESSION 217

Abstract 217

MARKER SYSTEM FOR PREPARING AND CHARACTERIZING HIGH-QUALITY HUMAN EMBRYONIC STEM CELLS 217

Abstract 217

Chapter-20: COMPANY PROFILES

TABLE 43 PUBLICLY TRADED COMPANIES IN THE REGENERATIVE MEDICINE INDUSTRY, AS OF JULY 1, 2009 218

AASTROM BIOSCIENCES, INC. 219

ADVANCED BIOHEALING, INC. 219

ADVANCED CELL TECHNOLOGY, INC. 220

AESCULAP, INC. 221

ALDAGEN, INC. 221

ALPHATEC SPINE, INC. 222

ANGIOTECH PHARMACEUTICALS, INC. 222

ARTERIOCYTE MEDICAL SYSTEMS, INC. 223

ARTHREX, INC. 223

ARTHROCARE CORPORATION 223

BIOMET, INC. 224

BIOMIMETIC THERAPEUTICS, INC. 224

BIOTISSUE TECHNOLOGIES GMBH 224

CAPSTONE THERAPEUTICS 225

CENTERPULSE ORTHOPAEDICS, INC. 226

CERAPEDICS, INC. 226

CITAGENIX, INC. 226

CONMED CORPORATION 227

CROSSCART INC. 228

CRYOLIFE, INC. 229

CURIS 230

CYTORI THERAPEUTICS, INC. 231

DEPUY ORTHOPAEDICS, INC. (UNIT OF THE DEPUY COMPANIES) 231

DJO SURGICAL 232

ESBATECH AG 232

ETEX CORPORATION 233

EXACTECH, INC. 234

FATE THERAPEUTICS, INC. 234

GARNET BIOTHERAPEUTICS 234

GENZYME BIOSURGERY 235

GERON CORPORATION 236

INTEGRA LIFESCIENCES HOLDING CORP. 236

ISOTIS ORTHOBIOLOGICS, INC. (INTEGRA ORTHOBIOLOGICS) 237

INTERNATIONAL STEM CELL 237

INTERPORE CROSS INTERNATIONAL 238

ISTO TECHNOLOGIES, INC. 239

KENSEY NASH CORPORATION 240

LIFECELL (A SUBSIDIARY OF KINETIC CONCEPTS, INC.) 241

MCEWEN CENTRE FOR REGENERATIVE MEDICINE 241

MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE 242

MEDTRONIC, INC. 242

MESOBLAST, LIMITED 243

NATIONAL CENTER FOR REGENERATIVE MEDICINE 243

NATIONAL TISSUE ENGINEERING CENTER (NTEC) 244

NEURALSTEM 245

NOVABONE PRODUCTS, LLC 246

NOVARTIS CORPORATION 246

NOVOCELL, INC. 246

OPEXA THERAPEUTICS 246

ORGANOGENESIS INC. 247

ORTHOFIX INTERNATIONAL N.V. 248

ORTHOPEUTICS, L.P. 248

ORTHOVITA, INC. 249

OSIRIS THERAPEUTICS, INC. 249

OSTEOTECH, INC. 250

PFIZER, INC. 250

PLURISTEM THERAPEUTICS 250

REGEN BIOLOGICS, INC. 251

RENEURON 252

RTI BIOLOGICS, INC. 252

SCIL TECHNOLOGY GMBH 252

SMITH AND NEPHEW 253

STEMCELLS, INC. 253

STEMCOR SYSTEMS, INC. 254

STRAUMANN USA LLC 254

STRYKER CORP. 255

SYNTHES, INC. 255

TENGION 256

TEPHA 257

THERMOGENESIS CORP. 257

TIGENIX N.V. 258

UCB S.A. (HEADQUARTERS) 259

WAKE FOREST INSTITUTE FOR REGENERATIVE MEDICINE 259

WRIGHT MEDICAL GROUP, INC. 260

ZIMMER HOLDINGS, INC. 261

OTHER ORGANIZATIONS INVOLVED IN REGENERATIVE MEDICINE R&D 261

ACADEMIC INSTITUTIONS 261

U.S. GOVERNMENT 262

OTHER SOCIETIES AND ORGANIZATIONS 262

Chapter-21: GLOSSARY OF KEY TERMS IN REGENERATIVE MEDICINE BUSINESS

GLOSSARY OF KEY TERMS 263

GLOSSARY OF KEY TERMS (CONTINUED) 264

GLOSSARY OF KEY TERMS (CONTINUED) 265

GLOSSARY OF KEY TERMS (CONTINUED) 266

GLOSSARY OF KEY TERMS (CONTINUED) 267

GLOSSARY OF KEY TERMS (CONTINUED) 268

GLOSSARY OF KEY TERMS (CONTINUED) 269

To order this report:

Regenerative Medicines: Bone and Joint Applications

http://www.reportlinker.com/p0157460/Regenerative-Medicines-Bone-and-Joint-Applications.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

More market research reports here!

Contact Nicolas Bombourg Reportlinker Email: nbo@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds Chinese Markets for Colon Cancer...
S
Reportlinker Adds Contract Pharmaceutical Manufact...